Turn Therapeutics (TTRX) Common Equity (2024 - 2026)

Turn Therapeutics' Common Equity history runs 3 years deep, the most recent figure standing at $6.1 million for Q1 2026.

• In Q1 2026, Common Equity rose 647.22% year-over-year to $6.1 million; the TTM figure through Mar 2026 stood at $6.1 million (up 647.22% YoY), while the FY2025 annual figure was $4.7 million, up 2741.42% from the prior year.
• Common Equity was $6.1 million for Q1 2026 at Turn Therapeutics, up from $4.7 million in the prior quarter.
• In the past five years, Common Equity ranged from a high of $6.1 million in Q1 2026 to a low of -$414299.0 in Q3 2024.
• Historically, Common Equity has averaged $1.9 million across 3 years, with a median of $661364.5 in 2025.
• Biggest YoY gain for Common Equity was 2741.42% in 2025; the steepest drop was 221.66% in 2025.
• A 3-year view of Common Equity shows it stood at -$177432.0 in 2024, then soared by 2741.42% to $4.7 million in 2025, then jumped by 30.53% to $6.1 million in 2026.
• The last three Common Equity figures came in at $6.1 million (Q1 2026), $4.7 million (Q4 2025), and $504019.0 (Q3 2025), per Business Quant data.